The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naldini, A.
Right arrow Articles by Presta, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naldini, A.
Right arrow Articles by Presta, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH
The Journal of Immunology, 2006, 177: 4267-4270.
Copyright © 2006 by The American Association of Immunologists, Inc.

CUTTING EDGE

Cutting Edge: IL-1beta Mediates the Proangiogenic Activity of Osteopontin-Activated Human Monocytes1

Antonella Naldini2,*, Daria Leali{dagger}, Annalisa Pucci*, Emilia Morena*, Fabio Carraro*, Beatrice Nico{ddagger}, Domenico Ribatti{ddagger} and Marco Presta{dagger}

* Unit of Neuroimmunophysiology, Department of Physiology, University of Siena, Siena, Italy; {dagger} Unit of General Pathology and Immunology, Department of Biomedical Sciences and Biotechnology, University of Brescia, Brescia, Italy; and {ddagger} Department of Human Anatomy and Histology, University of Bari, Bari, Italy


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Inflammation plays an important role in the onset of angiogenesis. In the present study, we show that osteopontin (OPN), a proinflammatory mediator involved in tissue repair, induces IL-1beta up-regulation in human monocytes. This was accompanied by the enhanced production of TNF-{alpha}, IL-8, and IL-6, a decreased release of IL-10, and increased p38 phosphorylation. The supernatants of OPN-treated monocytes were highly angiogenic when delivered on the chick embryo chorioallantoic membrane. The angiogenic response was completely abrogated by a neutralizing anti-IL-1 Ab, thus indicating that this cytokine represents the major proangiogenic factor expressed by OPN-activated monocytes. Accordingly, rIL-1beta mimicked the proangiogenic activity of OPN-treated monocyte supernatants, and IL-1R (type I) was found to be expressed in the chorioallantoic membrane. In conclusion, OPN-activated monocytes may contribute to the onset of angiogenesis through a mechanism mediated by IL-1beta.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
The causal relationship between inflammation and angiogenesis is now widely accepted (1); however, many of the molecular and cellular mechanisms mediating this relationship remain unresolved. The term angiogenic switch describes the expression of specific genes that alter the balance between pro- and antiangiogenic molecules that participate in blood vessel formation (2). Monocytes/macrophages produce direct and indirect inducers of angiogenesis, as well as angiogenic inhibitors (3, 4). Also, recent observations have shown that IL-1beta may act as a potent proangiogenic cytokine (5) and that administration of IL-1 receptor antagonist inhibits tumor growth and neovascularization (6).

Osteopontin (OPN)3, also known as early T lymphocyte-activating gene-1 (7), is a phosphorylated acidic RGD-containing glycoprotein that binds certain CD44 variants and integrin receptors (8). OPN exists both as an immobilized extracellular matrix component and as a soluble molecule implicated in inflammation, cell-mediated immunity, tissue remodeling, and tumor metastases (8, 9, 10). OPN acts as a proinflammatory cytokine that plays important roles in monocyte/macrophage functions (11, 12, 13). Experiments performed on OPN-null mice implicate OPN in Th1 cell-mediated immunity during infection, autoimmune demyelinating disease, rheumatoid arthritis, wound healing, and bone resorption (14).

In keeping with the tight cross-talk among angiogenic growth factors and cytokines, we have shown that OPN up-regulation in endothelial cells may represent a mechanism of amplification of growth factor-induced neovascularization (11). The experimental evidence suggests that OPN may affect angiogenesis indirectly via mononuclear phagocyte recruitment and up-regulation of the expression of monocyte-derived proangiogenic cytokine(s).

In the present study, we demonstrate that OPN activates a novel monocyte-mediated mechanism of neovascularization triggered by IL-1beta.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Reagents

Recombinant human OPN, recombinant fibroblast growth factor-2 (FGF-2), and mAb to IL-1beta, IL-8, and TNF-{alpha} were obtained from R&D Systems. Recombinant human IL-1beta was purchased from Endogen. The serum-free medium HYQCCM1 and FBS were obtained from HyClone. Mouse OPN and its RGD deletion mutant ({Delta}RGD-OPN) were expressed in Escherichia coli as GST fusion proteins, as described previously (11). Endotoxin levels were always <0.06 EU/ml (6 pg/ml), as determined by the Limulus amebocyte lysate method (Cambrex). LPS was purchased from Euroclone.

Monocyte preparation and culture

Human monocytes were obtained from buffy coats of healthy blood donors (through the courtesy of the Blood Center, Siena Medical Center) by Ficoll (Lympholyte-H; Cederlane Laboratories) and Percoll (Amersham Biosciences) gradients, as described previously (11). Where indicated, cells were incubated for 4–24 h with different concentrations of OPN in HYQCCM1 and 1% FBS. Then, conditioned medium (CM) was collected and evaluated either for cytokine content or for its angiogenic activity in the gelatin sponge/chick embryo chorioallantoic membrane (CAM) assay. In parallel, monocytes were lysed, and total RNA was extracted for quantitative RT-PCR (qRT-PCR) analysis.

Measurement of cytokines by ELISA

IL-1beta, TNF-{alpha}, IL-6, IL-8, and IL-10 concentrations were assessed on monocytes supernatants by ELISA using high-performance ELISA reagents (Euroclone). None of the assays showed cross-reactivity with other cytokines. The minimum detectable doses were for IL-1beta, TNF-{alpha}, IL-6, and IL-10 < 5 pg/ml and for IL-8 < 25 pg/ml.

RT-PCR and qRT-PCR

IL-1RI mRNA expression in control unstimulated CAM was analyzed by RT-PCR. Total RNA was extracted from CAM fragments using the TRIzol Reagent (Invitrogen Life Technologies). RNA samples (2 µg) were retrotranscribed with Ready-To-Go You-Prime First Strand Beads (Amersham Biosciences). PCR were performed on cDNA samples using the forward primer, 5'-TGCCATCTTGATCCTCAATG-3', and the reverse primer, 5'-TGGAAGCAAGCCATACACAC-3' (chicken IL-1RI: GenBank accession no. NM_205485). Amplified products were subjected to electrophoresis on agarose gel and visualized by ethidium bromide staining.

IL-1beta mRNA expression in OPN-treated monocytes was determined by qRT-PCR using a MJ MiniOpticon Cycler (Bio-Rad). Total RNA was isolated using RNAwiz (Ambion). First-strand cDNA synthesis was performed using a iScript cDNA Synthesis kit (Bio-Rad). qRT-PCR was performed using iTaq SYBR Green Supermix with ROX (Bio-Rad) and the following primers: IL-1beta forward, 5'-TGATGGCTTATTACAGTGGCAATG-3', and IL-1beta reverse, 5'-GTAGTGGTGGTGGGAGATTCG-3'; and beta-actin forward, 5'-CGCCGCCAGCTCACCATG-3', and beta-actin reverse, 5'-CACGATGGAGGGGAAGACGG-3' (GenBank accession no. for IL-1beta, NM000576, and for beta-actin, NM001101). Data were quantitatively analyzed on an MJ OpticonMonitor detection system (Bio-Rad). All values were expressed as fold increase relative to the expression of beta-actin.

Immunohistochemistry and Western blot analysis

IL-1RI immunodetection was performed on deparaffinized 5-µm CAM sections (15), using a goat polyclonal anti-mouse IL-1RI Ab (R&D Systems) and a preimmune goat serum as negative control.

For Western blot analysis, monocytes were treated with 100 nM OPN, and at different time points, cells were properly lysed. Aliquots (40 µg) of the extracted material were analyzed by Western blotting using rabbit polyclonal anti-phospho-p38 and anti-pan-p38 Abs (Cell Signaling Technology).

CAM assay

The CAM of fertilized White Leghorn chicken eggs were added, on day 8, with 1-mm3 sterilized gelatin sponges (Gelfoam Upjohn), as described previously (16). The sponges were loaded with 3 µl of PBS as negative control; 3 µl of PBS with 500 ng of FGF-2; 3 µl of CM from human monocytes pretreated with 100 nM OPN and added or not with a saturating dose (400 ng) of neutralizing anti-IL-1beta, anti-IL-8, or anti-TNF-{alpha} mAb; and 3 µl of PBS with 5 ng of IL-1beta. CAM were photographed in ovo with a stereomicroscope equipped with a camera and image analyzer system (Olympus Italia). At day 12, the angiogenic response was evaluated as the number of vessels converging toward the sponge.

Endothelial cell migration assay

The CM from control and OPN-treated monocytes were diluted (1/3 v/v) in HYQCCM1 medium plus 1.0% FCS and placed in the lower compartment of a chemotaxis microchamber (Neuroprobe). Murine aortic endothelial cells (50,000 cells/well) were added in the upper compartment. After 4 h at 37°C, cells migrated through the gelatin-coated polycarbonate filter (8-µm pore size; Neuroprobe) were stained with Diff-Quik (Baxter) and counted in triplicate (five fields per well).

Statistical analysis

Statistical significance between the experimental groups was determined using unpaired Student’s t test or one-way ANOVA with Dunnett’s post hoc test where appropriate.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
OPN triggers proinflammatory cytokine production in human monocytes

Human rOPN causes the rapid phosphorylation of p38 stress kinase when administered to freshly isolated monocytes from healthy blood donors (Fig. 1A). Activation of p38 is commonly associated with a proinflammatory response (17). Accordingly, OPN causes a significant increase in the levels of secreted IL-1beta protein, as well as of the proinflammatory/proangiogenic mediators TNF-{alpha}, IL-8, and IL-6 (Fig. 1, B–E). Also, OPN inhibits the release of the anti-inflammatory/antiangiogenic cytokine IL-10 when cells were activated with LPS (Fig. 1F), whereas it has no effect on IL-10 production in resting monocytes (data not shown).


Figure 1
View larger version (24K):
[in this window]
[in a new window]
  		FIGURE 1. OPN induces a proinflammatory response in human monocytes. A, OPN induces p38-MAPK activation in human monocytes. Human monocytes were treated with 100 nM OPN at different time points, and cellular extracts were probed with anti-phospho-p38 Ab and an anti-pan-p38 Ab, as a loading control. B–F, OPN modulates cytokine production in human monocytes. Human monocytes were cultured at 106 cells/ml in the presence of 100 nM OPN. After 18–24 h (4–6 h for IL-8) of culture, cell-free supernatants were obtained, and IL-1beta, TNF-{alpha}, IL-8, and IL-6 concentration was determined by ELISA. IL-10 determination was assessed from monocytes cultured in the presence of 100 nM OPN and LPS (0.1 µg/ml). The levels of IL-10 in the absence of LPS were undetectable (data not shown). Data are expressed as mean ± SEM (n = 3–6); *, p < 0.05 by Student’s t test.

 
The capacity of OPN to up-regulate IL-1beta in human monocytes was further investigated. Fig. 2 shows that the effect of OPN on IL-1beta protein production is dose dependent with an ED50 equal to ~50 ng/ml (Fig. 2A) and paralleled by an increase in steady-state levels of IL-1beta mRNA, as assessed by qRT-PCR (Fig. 2B). The effect was statistically significant 16–18 h after stimulation, but it was already detectable at 4–6 h (data not shown). IL-1beta was similarly induced by the rGST-OPN fusion protein and the GST-{Delta}RGD-OPN mutant deleted for the integrin-binding RGD sequence (11), whereas control GST was inactive (Fig. 2, C and D), indicating that integrin engagement is not responsible for IL-1beta up-regulation triggered by OPN in human monocytes.


Figure 2
View larger version (29K):
[in this window]
[in a new window]
  		FIGURE 2. OPN enhances IL-beta production in human monocytes. Monocytes were cultured with either different doses of OPN or 100 nM GST, GST-OPN, or GST-{Delta}RGD-OPN for 18–24 h. IL-1beta present in cell-free supernatants was determined by ELISA (A and C). Evaluation of IL-1beta mRNA expression in OPN-treated monocytes was determined by qRT-PCR (B and D). All values were expressed as fold increase relative to the expression of beta-actin. Data are expressed as mean ± SEM (n = 3); *, p < 0.05 by one-way ANOVA with Dunnett’s post hoc test.

 
Collectively, these results show that OPN induces the release of IL-1beta and other proinflammatory/proangiogenic cytokines, such as TNF-{alpha}, IL-8, and IL-6, and inhibits the production of antiinflammatory/antiangiogenic IL-10 in human monocytes.

OPN-activated monocytes induces angiogenesis via IL-1beta production

The above observations are in agreement with the hypothesis that OPN may cause a switch of the angiogenic balance in human monocytes that favors the neovascularization process. Accordingly, when tested in a Boyden chamber assay, the CM from OPN-treated monocytes exerted a chemotactic response for murine aortic endothelial cells significantly higher than that triggered by the CM of control monocytes (Fig. 3). To assess this hypothesis in vivo, the CM from OPN-treated monocytes was delivered onto the CAM at day 8 of development. At day 12, implants were surrounded by numerous allantoic neovessels developing radially toward the implant in a "spoked-wheel" pattern (Fig. 3B). The response was similar to that elicited by the delivery of human rFGF-2, here used as a positive control (16) (mean number of vessels equal to 35 ± 5 and 32 ± 5 for CM and FGF-2, respectively). It must be pointed out that no significant angiogenic response was observed when fresh medium containing 100 nM OPN, the same dose used to stimulate human monocytes, was applied directly onto the CAM (data not shown). Indeed, this treatment results in the delivery of 18 ng of OPN per embryo, a dose five times lower than the minimal angiogenic dose of the cytokine (11). Thus, these observations confirm the hypothesis that OPN treatment triggers a proangiogenic phenotype in human monocytes.


Figure 3
View larger version (70K):
[in this window]
[in a new window]
  		FIGURE 3. OPN-treated monocytes induce endothelial cell chemotaxis and angiogenesis in the CAM through IL-1beta. A, Murine aortic endothelial cells were assessed for their capacity to migrate in response to CM from control and OPN-treated monocytes in a Boyden chamber assay. After 4 h, cells that migrated through the filter were counted in triplicate (five fields per well) at x250 magnification. Control values obtained in fresh medium (52 ± 8 cells/field) were subtracted from all the data. *, Significantly different from control CM, p < 0.01 by Student’s t test. B, Gelatin sponges were adsorbed with: vehicle (PBS); rFGF-2; CM from OPN-treated monocytes in the absence (CM) or in the presence of neutralizing anti-IL-1beta (CM + anti-IL-1beta), anti-IL-8 (CM + anti-IL-8), or anti-TNF-{alpha} (CM + anti-TNF-{alpha}) mAb; and rIL-1beta. Sponges were then implanted onto the CAM. At day 12, blood vessels entering the sponges were counted. Data are the mean ± SD of 20 embryos. *, Significantly different from CM, p < 0.05 by Student’s t test. C–E, Macroscopic images of CAM treated with CM from OPN-treated monocytes in the absence (C) or in the presence (D) of a neutralizing anti-IL-1beta mAb. Note the significantly reduced angiogenic response in D, similar to that observed in the CAM treated with PBS (E). F and G, IL-1RI expression in the CAM. RT-PCR was performed using specific chicken IL-1RI primers on retrotranscribed CAM mRNA (+RT). Nonretrotranscribed CAM mRNA (–RT) was used as control (F). Paraffin-embedded CAM sections were nuclear counterstained and decorated with affinity-purified goat polyclonal anti-IL-1RI Ab on day 12. IL-1RI immunoreactivity was evident in the endothelium lining the blood vessels (G). Original magnification, x400. No specific signal was observed in CAM in which primary Ab was replaced by preimmune rabbit serum (data not shown).

 
To assess the contribution of IL-1beta to this response, CM from OPN-treated monocytes was preincubated with a saturating dose of neutralizing anti-IL-1beta mAb before being delivered onto the CAM. As shown in Fig. 3, the Ab completely abolished the neovascular response triggered by the CM, the mean number of blood vessel converging toward the implant being similar (10 ± 3) to that observed in control CAM treated with PBS-loaded implants (7 ± 3). In contrast, neutralizing anti-IL-8 or anti-TNF-{alpha} Abs did not affect the neovascular response induced by the CM.

In keeping with these observations, recombinant human IL-1beta (5 ng per embryo) caused a potent angiogenic response in the CAM, similar to that induced by the CM from OPN-treated monocytes (Fig. 3). IL-1beta exerts its biological effects by interacting with cognate IL-1R (18). Accordingly, IL-1RI mRNA was detectable in CAM extracts by RT-PCR, and IL-1RI protein was localized on chick embryo endothelium, as shown by immunostaining of CAM sections (Fig. 3).


   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In the present article, we demonstrate that OPN induces a proangiogenic switch in human monocytes characterized by IL-1beta, TNF-{alpha}, IL-8, and IL-6 up-regulation and by IL-10 down-modulation. This extends previous observations about the capacity of OPN to induce proangiogenic cytokines and chemokines (13). Accordingly, the CM from OPN-treated monocytes is endowed with a potent angiogenic activity that is fully neutralized by anti-IL-1beta Ab but not by anti-TNF-{alpha} or anti-IL-8 Ab. This observation points out the relevance of IL-1beta in OPN-induced angiogenesis; however, we cannot exclude a role for other proangiogenic cytokines and chemokines, such as CXCL1, CXCL2, and CXCL5, in the angiogenic response exerted by OPN.

IL-1 is a strong inducer of the hypoxia-inducible factor-1{alpha} (19, 20), which positively modulates the transcription of the angiogenic growth factors vascular endothelial growth factor and FGF-2 (21). However, neither vascular endothelial growth factor or FGF-2 up-regulation was observed in human monocytes treated with OPN (data not shown), ruling out the possibility that these growth factors may be involved in OPN-mediated neovascularization.

These observations support the hypothesis that the proangiogenic activity of OPN (11) is due, at least in part, to an indirect mechanism of action consequent to the recruitment of proangiogenic monocytes and up-regulation of proinflammatory cytokines. Several experimental evidences support this hypothesis (22). OPN induces a chemotactic response on isolated human monocytes, and OPN-induced angiogenesis is paralleled by the recruitment of a massive mononuclear cell infiltrate (11). In the same study, the GST-{Delta}RGD-OPN mutant deleted for the integrin-binding RGD sequence retained a chemotactic activity for human monocytes and a proangiogenic potential in the CAM assay similar to that shown by the wild-type molecule (11). Accordingly, in the present study, both GST-OPN and GST-{Delta}RGD-OPN cause IL-1beta up-regulation in human monocytes. Taken together, the data indicate that the IL-1beta-mediated neovascular response triggered by OPN occurs via an integrin-independent mechanism of action, possibly consequent to OPN/CD44 receptor interaction (12).

Monocyte/macrophage functions are deeply affected by OPN (7, 8). OPN is also implicated in Th1 cell-mediated immunity during infection, autoimmune demyelinating disease, rheumatoid arthritis, wound healing, and bone resorption (14, 23, 24, 25). All these conditions are characterized by mononuclear phagocyte involvement, as well as by the presence of proinflammatory cytokines, including IL-1beta (26). Monocytes express a variety of angiogenic factors (27, 28, 29). Among them, IL-1beta plays a pivotal role in angiogenesis (5). In the present study, in keeping with a putative role for recruited monocytes in OPN-triggered angiogenesis, OPN induces the expression and release of IL-1beta whose neutralization completely abolishes neovascularization triggered by OPN-activated monocytes. Accordingly, other authors have reported previously that neovascularization is impaired in either IL-1beta or OPN-null mice (5, 30).

Thus, our data indicate that, through monocyte activation, IL-1beta is the master regulator of OPN-induced angiogenesis. The proinflammatory/proangiogenic response induced by OPN may represent an additional mechanism for promoting neovascularization in different physiopathological conditions, including wound healing and tumor growth.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by grants from MIUR (Cofin 2004) and Fondazione MPS (to A.N.) and from MIUR (Centro di Eccellenza IDET, FIRB 2001, Cofin 2004), Fondazione G. Berlucchi, Istituto Superiore Sanità (Progetto Oncotecnologico), and Associazione Italiana per la Ricerca sul Cancro (Italy) (to M.P.). Back

2 Address correspondence and reprint requests to Dr. Antonella Naldini, Unit of Neuroimmunophysiology, Department of Physiology, University of Siena, Via Aldo Moro, 53100 Siena, Italy. E-mail address: Naldini{at}Unisi.it Back

3 Abbreviations used in this paper: OPN, osteopontin; FGF-2, fibroblast growth factor-2; CM, conditioned medium; CAM, chorioallantoic membrane; qRT-PCR, quantitative RT-PCR; RGD, Arg-Gly-Asp. Back

Received for publication April 6, 2006. Accepted for publication July 26, 2006.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Coussens, L. M., Z. Werb. 2002. Inflammation and cancer. Nature 420: 860-867. [Medline]
  2. Kerbel, R., J. Folkman. 2002. Clinical translation of angiogenesis inhibitors. Nat. Rev. Cancer 2: 727-739. [Medline]
  3. Lingen, M. W.. 2001. Role of leukocytes and endothelial cells in the development of angiogenesis in inflammation and wound healing. Arch. Pathol. Lab. Med. 125: 67-71. [Medline]
  4. O’Reilly, M. S., T. Boehm, Y. Shing, N. Fukai, G. Vasios, W. S. Lane, E. Flynn, J. R. Birkhead, B. R. Olsen, J. Folkman. 1997. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285. [Medline]
  5. Voronov, E., D. S. Shouval, Y. Krelin, E. Cagnano, D. Benharroch, Y. Iwakura, C. A. Dinarello, R. N. Apte. 2003. IL-1 is required for tumor invasiveness and angiogenesis. Proc. Natl. Acad. Sci. USA 100: 2645-2650. [Abstract/Free Full Text]
  6. Bar, D., R. N. Apte, E. Voronov, C. A. Dinarello, S. Cohen. 2004. A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development. FASEB J. 18: 161-163. [Abstract/Free Full Text]
  7. O’Regan, A. W., G. J. Nau, G. L. Chupp, J. S. Berman. 2000. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol. Today 21: 475-478. [Medline]
  8. Denhardt, D. T., M. Noda, A. W. O’Regan, D. Pavlin, J. S. Berman. 2001. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107: 1055-1061. [Medline]
  9. Rittling, S. R., Y. Chen, F. Feng, Y. Wu. 2002. Tumor-derived osteopontin is soluble, not matrix associated. J. Biol. Chem. 277: 9175-9182. [Abstract/Free Full Text]
  10. Denhardt, D. T., D. Mistretta, A. F. Chambers, S. Krishna, J. F. Porter, S. Raghuram, S. R. Rittling. 2003. Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter. Clin. Exp. Metastasis 20: 77-84. [Medline]
  11. Leali, D., P. Dell’Era, H. Stabile, B. Sennino, A. F. Chambers, A. Naldini, S. Sozzani, B. Nico, D. Ribatti, M. Presta. 2003. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J. Immunol. 171: 1085-1093. [Abstract/Free Full Text]
  12. Zhu, B., K. Suzuki, H. A. Goldberg, S. R. Rittling, D. T. Denhardt, C. A. McCulloch, J. Sodek. 2004. Osteopontin modulates CD44-dependent chemotaxis of peritoneal macrophages through G-protein-coupled receptors: evidence of a role for an intracellular form of osteopontin. J. Cell. Physiol. 198: 155-167. [Medline]
  13. Xu, G., H. Nie, N. Li, W. Zheng, D. Zhang, G. Feng, L. Ni, R. Xu, J. Hong, J. Z. Zhang. 2005. Role of osteopontin in amplification and perpetuation of rheumatoid synovitis. J. Clin. Invest. 115: 1060-1067. [Medline]
  14. Yumoto, K., M. Ishijima, S. R. Rittling, K. Tsuji, Y. Tsuchiya, S. Kon, A. Nifuji, T. Uede, D. T. Denhardt, M. Noda. 2002. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. USA 99: 4556-4561. [Abstract/Free Full Text]
  15. Ribatti, D., B. Nico, A. Vacca, L. Roncali. 1999. Localization of factor VIII-related antigen in the endothelium of the chick embryo chorioallantoic membrane. Histochem. Cell Biol. 112: 447-450. [Medline]
  16. Ribatti, D., A. Gualandris, M. Bastaki, A. Vacca, M. Iurlaro, L. Roncali, M. Presta. 1997. New model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic membrane: the gelatin sponge/chorioallantoic membrane assay. J. Vasc. Res. 34: 455-463. [Medline]
  17. Kyriakis, J. M., J. Avruch. 2001. Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81: 807-869. [Abstract/Free Full Text]
  18. Dinarello, C. A.. 1998. Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist. Int. Rev. Immunol. 16: 457-499. [Medline]
  19. Hellwig-Burgel, T., K. Rutkowski, E. Metzen, J. Fandrey, W. Jelkmann. 1999. Interleukin-1beta and tumor necrosis factor {alpha} stimulate DNA binding of hypoxia-inducible factor-1. Blood 94: 1561-1567. [Abstract/Free Full Text]
  20. Jung, Y. J., J. S. Isaacs, S. Lee, J. Trepel, L. Neckers. 2003. IL-1beta-mediated up-regulation of HIF-1{alpha} via an NF{kappa}B/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J. 17: 2115-2117. [Abstract/Free Full Text]
  21. Calvani, M., A. Rapisarda, B. Uranchimeg, R. H. Shoemaker, G. Melillo. 2006. Hypoxic induction of an HIF-1{alpha}-dependent bFGF autocrine loop drives angiogenesis in human endothelial cells. Blood 107: 2705-2712. [Abstract/Free Full Text]
  22. Giachelli, C. M., D. Lombardi, R. J. Johnson, C. E. Murry, M. Almeida. 1998. Evidence for a role of osteopontin in macrophage infiltration in response to pathological stimuli in vivo. Am. J. Pathol. 152: 353-358. [Abstract]
  23. Yoshitake, H., S. R. Rittling, D. T. Denhardt, M. Noda. 1999. Osteopontin-deficient mice are resistant to ovariectomy-induced bone resorption. Proc. Natl. Acad. Sci. USA 96: 8156-8160. [Abstract/Free Full Text]
  24. Ashkar, S., G. F. Weber, V. Panoutsakopoulou, M. E. Sanchirico, M. Jansson, S. Zawaideh, S. R. Rittling, D. T. Denhardt, M. J. Glimcher, H. Cantor. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864. [Abstract/Free Full Text]
  25. Liaw, L., D. E. Birk, C. B. Ballas, J. S. Whitsitt, J. M. Davidson, B. L. Hogan. 1998. Altered wound healing in mice lacking a functional osteopontin gene (spp1). J. Clin. Invest. 101: 1468-1478. [Medline]
  26. Dinarello, C. A.. 2000. Proinflammatory cytokines. Chest 118: 503-508. [Abstract/Free Full Text]
  27. Jackson, J. R., M. P. Seed, C. H. Kircher, D. A. Willoughby, J. D. Winkler. 1997. The codependence of angiogenesis and chronic inflammation. FASEB J. 11: 457-465. [Abstract]
  28. Sunderkotter, C., K. Steinbrink, M. Goebeler, R. Bhardwaj, C. Sorg. 1994. Macrophages and angiogenesis. J. Leukocyte Biol. 55: 410-422. [Abstract]
  29. Leibovich, S. J., P. J. Polverini, H. M. Shepard, D. M. Wiseman, V. Shively, N. Nuseir. 1987. Macrophage-induced angiogenesis is mediated by tumour necrosis factor {alpha}. Nature 329: 630-632. [Medline]
  30. Asou, Y., S. R. Rittling, H. Yoshitake, K. Tsuji, K. Shinomiya, A. Nifuji, D. T. Denhardt, M. Noda. 2001. Osteopontin facilitates angiogenesis, accumulation of osteoclasts, and resorption in ectopic bone. Endocrinology 142: 1325-1332. [Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
H. Hasturk, A. Kantarci, E. Goguet-Surmenian, A. Blackwood, C. Andry, C. N. Serhan, and T. E. Van Dyke
Resolvin E1 Regulates Inflammation at the Cellular and Tissue Level and Restores Tissue Homeostasis In Vivo
J. Immunol., November 15, 2007; 179(10): 7021 - 7029.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Gomez-Ambrosi, V. Catalan, B. Ramirez, A. Rodriguez, I. Colina, C. Silva, F. Rotellar, C. Mugueta, M. J. Gil, J. A. Cienfuegos, et al.
Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in Obesity
J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3719 - 3727.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naldini, A.
Right arrow Articles by Presta, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naldini, A.
Right arrow Articles by Presta, M.
Right arrowPubmed/NCBI databases
*Substance via MeSH

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS